Phase II study of gemcitabine in recurrent platinum-and paclitaxel-resistant ovarian cancer.
about
Gemcitabine for platinum-resistant or recurrent ovarian cancerRecurrent epithelial ovarian cancer: pharmacotherapy and novel therapeutics.Heavily pretreated ovarian cancer patients treated by single-agent gemcitabine. A retrospective outcome comparison between platinum-sensitive and platinum-resistant patients.Response to and toxicity of gemcitabine for recurrent ovarian cancer according to number of previous chemotherapy regimens.Inhibition of carboplatin-induced DNA interstrand cross-link repair by gemcitabine in patients receiving these drugs for platinum-resistant ovarian cancer.Optimal therapy for platinum-resistant recurrent ovarian cancer: doxorubicin, gemcitabine or topotecan?Recent progress in the diagnosis and treatment of ovarian cancerA phase II feasibility study of carboplatin followed by sequential weekly paclitaxel and gemcitabine as first-line treatment for ovarian cancer.Effects of sequential paclitaxel-carboplatin followed by gemcitabine-based chemotherapy compared with paclitaxel-carboplatin therapy administered to patients with advanced epithelial ovarian cancer: A retrospective, STROBE-compliant study.Pertuzumab for the treatment of ovarian cancer.Recurrent ovarian cancer: when and how to treat.Low-grade serous carcinoma: molecular features and contemporary treatment strategies.The efficacy and toxicity of belotecan (CKD-602), a camptothericin analogue topoisomerase I inhibitor, in patients with recurrent or refractory epithelial ovarian cancer.Role of gemcitabine in the treatment of ovarian cancer.Second-line treatment with intravenous gemcitabine and oral etoposide in platinum-resistant advanced ovarian cancer patients: results of a phase II study.p53-reactive T cells are associated with clinical benefit in patients with platinum-resistant epithelial ovarian cancer after treatment with a p53 vaccine and gemcitabine chemotherapy.A novel anticancer theranostic pro-prodrug based on hypoxia and photo sequential control.Intermediate-dose melphalan with stem-cell support in platinum-refractory ovarian cancer.
P2860
Q24241162-E751CED4-622E-4D3D-9640-A9640AFBD1D7Q30444706-4440B3BC-61EA-46CE-A15F-D9399736EDC2Q33371474-B3B8D775-D8AF-4F43-BB6E-CF3A4B27448AQ33437512-7925B7CF-FD95-4FE4-881E-6011F9CCDFC3Q34811103-BF856A7D-6D0F-4C51-B1CA-363FFEA1D964Q36488198-67A550E9-71DB-4815-B3E2-390582E76B32Q36622857-4F9919CC-196D-4A2D-893E-2C7D4F4C1C85Q36626071-C1049FEE-40BA-4D3D-BB56-DE6BD90D4CE1Q37530604-7710DA5E-66E9-450A-A5DF-FD0E661AC640Q37750891-48AD6790-1116-4EC2-A421-E61944C65D34Q37951860-87C57E89-0B6C-4A1D-9DB5-11CFE73F38D3Q38514737-FB1332D6-DDBA-4E19-8CE3-5DFB928CADFBQ43010573-1E024312-F789-440B-8463-51F03CC2DA41Q43267035-B8041AD2-D01A-459A-ADCE-898E2A93AC37Q45076685-38E0246A-F0A0-4EC9-9FF2-8DE37C45BB1EQ47561666-EC0532EF-C877-40E3-9619-8E007292BE8DQ52981912-DDC43B4E-5EEC-4ECD-9DBD-46566CD4FBD6Q53897263-A32A999C-2A12-41CC-A1F2-51068F5C5036
P2860
Phase II study of gemcitabine in recurrent platinum-and paclitaxel-resistant ovarian cancer.
description
2003 nî lūn-bûn
@nan
2003 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի մարտին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Phase II study of gemcitabine ...... axel-resistant ovarian cancer.
@ast
Phase II study of gemcitabine ...... axel-resistant ovarian cancer.
@en
type
label
Phase II study of gemcitabine ...... axel-resistant ovarian cancer.
@ast
Phase II study of gemcitabine ...... axel-resistant ovarian cancer.
@en
prefLabel
Phase II study of gemcitabine ...... axel-resistant ovarian cancer.
@ast
Phase II study of gemcitabine ...... axel-resistant ovarian cancer.
@en
P2093
P1433
P1476
Phase II study of gemcitabine ...... axel-resistant ovarian cancer.
@en
P2093
Frederic Amant
Giovanni Scambia
Giuseppe D'Agostino
Patrick Berteloot
P304
P356
10.1016/S0090-8258(03)00011-8
P407
P577
2003-03-01T00:00:00Z